RxDoctor Payments Data

Jason Becker, DO

Pulmonary Disease · Sewell, NJNPI 1801177878

Payments from drug & device makers

$1,195in general payments, 2019–2025

Across 14 payments — averaging $85.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veran Medical Technologies, Inc.$779
  • Pulmonx Corporation$146
  • Intuitive Surgical$109
  • GSK$72
  • Insmed, Inc.$34
  • AstraZeneca$20
  • plus $35 from 2 others

What the payments were for

  • Travel & lodging$62152%
  • Food & beverage$55847%
  • Education$161%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,195 in reported general payments places this provider in the 40th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$113,664
Medicare patients
465
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$73,990
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr101$68,633
Dupixent PenDupilumab13$46,475
Incruse ElliptaUmeclidinium Bromide52$41,492
Breo ElliptaFluticasone/Vilanterol56$35,975
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$35,657
Spiriva RespimatTiotropium Bromide32$31,418
EliquisApixaban16$19,652
Albuterol Sulfate HfaAlbuterol Sulfate255$8,495
Advair HfaFluticasone Propion/Salmeterol11$8,212
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$8,099
Fluticasone-VilanterolFluticasone/Vilanterol14$5,689
Ventolin HfaAlbuterol Sulfate67$3,991
Montelukast Sodium82$922
Azithromycin33$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$72$220,090260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →